[{"id":"7b997a62-44fb-4062-866a-13def962969c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04908813","created_at":"2021-06-01T17:53:32.817Z","updated_at":"2024-07-02T16:35:09.664Z","phase":"Phase 2","brief_title":"Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer","source_id_and_acronym":"NCT04908813","lead_sponsor":"Shanghai Henlius Biotech","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • capecitabine • oxaliplatin • HLX22"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 09/29/2021","start_date":" 09/29/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-04-15"},{"id":"7793e5f8-1d21-4568-afa9-aca3de6db9c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03916094","created_at":"2021-01-18T19:15:55.460Z","updated_at":"2024-07-02T16:36:10.901Z","phase":"Phase 1","brief_title":"Evaluate Safety, Tolerability and Pharmacokinetics of HLX22 in Patients With Advanced Solid Tumors Overexpressing HER2","source_id_and_acronym":"NCT03916094","lead_sponsor":"Shanghai Henlius Biotech","biomarkers":" EGFR • HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 overexpression • HER-2 mutation","tags":["EGFR • HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 overexpression • HER-2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLX22"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 07/31/2019","start_date":" 07/31/2019","primary_txt":" Primary completion: 01/04/2021","primary_completion_date":" 01/04/2021","study_txt":" Completion: 12/27/2021","study_completion_date":" 12/27/2021","last_update_posted":"2022-05-05"},{"id":"13801bc2-a2e8-497b-9060-1fd9355fe93c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05320874","created_at":"2022-04-11T13:52:59.045Z","updated_at":"2025-02-25T17:12:10.318Z","phase":"Phase 1","brief_title":"A Study of KM257 in Patients With Advanced HER2-positive or Expressing Solid Tumors.","source_id_and_acronym":"NCT05320874","lead_sponsor":"Xuanzhu Biopharmaceutical Co., Ltd.","biomarkers":" HER-2 • KRAS • BRAF • NRAS","pipe":" | ","alterations":" HER-2 positive • BRAF V600E • KRAS mutation • NRAS mutation • BRAF V600 • HER-2 expression","tags":["HER-2 • KRAS • BRAF • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • BRAF V600E • KRAS mutation • NRAS mutation • BRAF V600 • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • paclitaxel • docetaxel • capecitabine • irinotecan • XZP-KM257"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 232","initiation":"Initiation: 04/01/2022","start_date":" 04/01/2022","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2022-04-11"},{"id":"93901ec6-cb53-4006-986c-b326980ea647","acronym":"","url":"https://clinicaltrials.gov/study/NCT04501770","created_at":"2021-01-18T21:33:47.632Z","updated_at":"2024-07-02T16:36:26.942Z","phase":"Phase 1","brief_title":"A Study of M802 (HER2 and CD3) in HER2-Positive Advanced Solid Tumors","source_id_and_acronym":"NCT04501770","lead_sponsor":"Wuhan YZY Biopharma Co., Ltd.","biomarkers":" CEACAM5 • MUC16 • CA 19-9","pipe":" | ","alterations":" HER-2 positive • HER-2 expression • CEACAM5 expression • MUC16 expression","tags":["CEACAM5 • MUC16 • CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 expression • CEACAM5 expression • MUC16 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e M802"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 08/28/2021","start_date":" 08/28/2021","primary_txt":" Primary completion: 11/30/2023","primary_completion_date":" 11/30/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2021-08-04"},{"id":"f3b55f6a-113f-4fde-98ff-9a7e2c463d01","acronym":"","url":"https://clinicaltrials.gov/study/NCT04164615","created_at":"2021-01-18T20:19:22.079Z","updated_at":"2024-07-02T16:36:53.648Z","phase":"Phase 3","brief_title":"Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody (GB221) for Injection","source_id_and_acronym":"NCT04164615","lead_sponsor":"Genor Biopharma Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • GB221 (coprelotamab)"],"overall_status":"Unknown status","enrollment":" Enrollment 336","initiation":"Initiation: 11/24/2016","start_date":" 11/24/2016","primary_txt":" Primary completion: 07/01/2020","primary_completion_date":" 07/01/2020","study_txt":" Completion: 11/01/2020","study_completion_date":" 11/01/2020","last_update_posted":"2019-11-15"}]